Open Access Collection: Yeast 2.0 – synthetic biology for strain engineering

Open Access Collection: Yeast 2.0 – synthetic biology for strain engineering
Like

Share this post

Choose a social network to share with, or copy the URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

How can researchers explore the vast space of possible genomes to build strains for bioengineering goals? Presented in Nature Communications is one answer to that question: SCRaMbLE – Synthetic Chromosome Rearrangement and Modification by Lox-P mediated Evolution.   Built into the architecture of the synthetic chromosomes being constructed as part of Sc2.0, SCRaMbLE allows for the rapid rearrangement of chromosomes allowing for selection by end product titre and tolerance to stressful conditions.  The papers presented here (www.nature.com/collections/ncomms-syntheticyeast) are the first set to demonstrate the power of this technology and the applicability to metabolic engineering, synthetic biology and industrial biotechnology. 

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Follow the Topic

Biotechnology
Life Sciences > Biological Sciences > Biotechnology

Related Collections

With Collections, you can get published faster and increase your visibility.

Women's Health

A selection of recent articles that highlight issues relevant to the treatment of neurological and psychiatric disorders in women.

Publishing Model: Hybrid

Deadline: Ongoing

Tumor Microenvironment Crosstalk and Therapeutic Implications

With this cross-journal Collection, the editors at Nature Immunology, Nature Communications, Communications Medicine and Scientific Reports invite manuscripts that highlight cutting-edge research on TME crosstalk and its therapeutic implications. Topics of interest include immune modulation and checkpoint pathways, cancer-associated fibroblasts and stromal remodeling, angiogenesis and vascular normalization, metabolic reprogramming within the TME, and the role of microbiota in tumor-immune dynamics. We also welcome studies on novel therapeutic approaches that exploit TME vulnerabilities to advance cancer treatment.

Publishing Model: Hybrid

Deadline: Nov 02, 2026